GlassScriptPhysician profile
Aaron J Porter
NPI 1528058252
$10,406.09
in general payments reported to CMS, 2019-2025
22 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $550 · 2021: $1,295 · 2022: $2,014 · 2023: $1,762 · 2024: $1,470 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,477.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,300.70 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Allergan, INC. | $854.74 | 2020-2022 | |
| Abbvie INC. | $723.76 | 2022-2025 | |
| Mallinckrodt Enterprises LLC | $534.15 | 2019 | |
| Glaukos Corporation | $525.09 | 2019-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Carl Zeiss Meditec, INC. | $226.78 | 2019 | |
| Mallinckrodt Hospital Products INC. | $192.65 | 2020-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $120.73 | 2022-2024 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.13 | 2019 | |
| Ivantis, INC | $117.25 | 2021 | |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $111.10 | 2025 | |
| Sight Sciences, INC. | $98.10 | 2021-2025 | Omni Surgical System |
| Ocular Therapeutix, INC. | $95.88 | 2022-2025 | Dextenza |
| Johnson & Johnson Vision Care, INC. | $65.29 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $65.17 | 2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $60.83 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Alcon Research LLC | $59.24 | 2019 | |
| Beaver-Visitec International, INC. | $42.74 | 2021-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $34.70 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $23.70 | 2024 | Xiidra |
| Janssen Pharmaceuticals, INC | $17.89 | 2024 | Xarelto |
| Dompe US, INC. | $17.47 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.